Naxitamab (Ganglioside GD2) Antibody, Monoclonal | 10-932

Naxitamab (Ganglioside GD2) Antibody, Monoclonal | 10-932 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Chimeric / Ganglioside GD2 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: Hu3F8

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Naxitamab is humanized monoclonal antibody that targets GD2 antigen. GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including tumors such as neuroblastoma, melanoma, and osteosarcoma. Naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system by binding to the GD2 antigen on the surface of the tumor, thereby achieving the effect of killing the tumor.